君實生物(01877.HK)口服小分子藥物VV116獲烏茲別克新冠治療緊急使用授權
君實生物(01877.HK)(688180.SH)表示,旗下口服核(甘)類抗新冠病毒藥物VV116,於12月31日獲烏茲別克衛生部批準緊急使用授權,用於治療2019新型冠狀病毒病。
公司表示,VV116由中國科學院上海藥物研究所、中國科學院武漢病毒研究所、中國科學院新疆理化技術研究所、旺山旺水、中國科學院中亞藥物研發中心共同研發,於10月與旺山旺水達成全球範圍臨牀開發和產業化工作合作,目前正在中國同步開展臨牀研究。
君實生物現報53.85元,升近8.7%,成交額約2.29億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.